COCHW
Envoy Medical, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.04
−1.74%Aug 27, 2026, 00:00 UTC
Envoy Medical, Inc. appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance, effective August 24, 2026.
Aug 10, 2026, 12:00 UTC
Envoy Medical reported financial results for the second quarter ended June 30, 2026, on August 10, 2026.
Source:Jul 21, 2026, 13:17 UTC
Envoy Medical announced that all 56 patients in its pivotal clinical trial for the Acclaim cochlear implant have passed the three-month visit milestone.
Source:Jun 30, 2026, 12:30 UTC
Envoy Medical submitted the first module of its Modular Premarket Approval application to the FDA for its breakthrough-designated hearing device.
Jun 25, 2026, 12:30 UTC
Envoy Medical terminated its at-the-market equity facility effective June 24, 2026.
Source:Jun 25, 2026, 00:00 UTC
Envoy Medical, Inc. appointed Brent Lucas as Chief Executive Officer effective June 19, 2026, with compensation including a base salary of $420,000, a cash bonus target of $105,000, and equity grants of stock options and restricted stock units.